Mitchell Elkind tried not to be a doctor. "My father is an expert in headache, so from an early age I was surrounded by people interested in the brain", Elkind tells *The Lancet Neurology*. Raised in New Rochelle, New York, USA, Elkind sought to forge his own, non-medical, path. Still, the mysteries of mind and brain beckoned, so he studied philosophy at Harvard University, along with premedical courses, and then travelled to the UK, where he studied the history of neurology and philosophy of the mind at Cambridge University. "I'm fascinated by the dualism of mind and body, and was thrilled to read about the approaches of famous neurologists, like Hughlings Jackson, to this conundrum", he explains.

While studying for his medical degree at Harvard, he realised that neurology felt a natural fit. "I enjoyed the logic of neuroscience. The brain, spinal cord, nerves---we logically work out where patients' problems originate", he explains. During his residency at Massachusetts General Hospital, Elkind met patients with almost every neurological condition. "The ways in which seizures could lead to changes in the mind especially fascinated me. I wondered about the role of neurological disease in art and creativity; was brain disease playing a role in the creativity of artists like Van Gogh or Dostoevsky?" But in the mid-1990s, so-called intravenous clot busters were beginning to be used to treat stroke, and he began to focus on cerebrovascular disease. "Stroke, previously something we couldn't do much about, was suddenly the most exciting area," he recalls.

During his training at Massachusetts General Hospital, Elkind had the chance to learn from giants in the field of stroke neurology, including the late C Miller Fisher and Walter Koroshetz---now Director of the US National Institute of Neurological Disorders and Stroke. He completed a fellowship in vascular neurology and neuroepidemiology at Columbia University Medical Center under the mentorship of one of the top stroke epidemiologists, Ralph Sacco. One early paper published with Sacco in [JAMA](https://doi.org/10.1001/jama.281.1.53){#interrefs10}, on moderate alcohol consumption offering protection from stroke, led to multiple media appearances to discuss the findings. He laughs that "some friends still call me Dr Cocktail."

Elkind has been involved in the Northern Manhattan Study (NOMAS), an epidemiological study of stroke risk factors, for more than two decades. His [analyses](https://doi.org/10.1001/archneurol.2009.271){#interrefs20} of inflammation and infection as risk factors for stroke show that evidence of past or chronic infection with common bacteria and viruses might contribute to a future risk of stroke, carotid artery disease, and even cognitive decline. Additionally, he and his colleagues found that acute infections, such as influenza or sepsis, can trigger stroke. He now hopes to study the association of other infections with stroke and dementia. This area might be particularly relevant now in the COVID-19 era, as there is growing evidence that the novel coronavirus can cause abnormal clotting and stroke in some patients.

"Mitch had a vision from the beginning that chronic infection and inflammation were novel stroke risk factors and he knew exactly what he wanted to do", says Ralph Sacco, Professor and Olemberg Chair of Neurology at the Miller School of Medicine, University of Miami, FL, USA. "He quickly established this independent line of investigation within NOMAS. From the beginning, he nurtured the idea, obtained funding, and became a leader in this exciting and expanding area."

His major current focus is as a lead investigator of the [ARCADIA trial](https://doi.org/10.1177/1747493018799981){#interrefs30} of apixaban versus aspirin for atrial cardiopathy in cryptogenic stroke, working with a team including Hooman Kamel at Weill Cornell Medicine, and Will Longstreth and David Tirschwell at the University of Washington. The study involves approximately 175 sites across the USA and Canada, and is almost halfway through completion. "Atrial cardiopathy is best described as dysfunction in the small chamber of the heart, the atrium, and is related to atrial fibrillation, a major risk factor for stroke in older adults", he explains. "Our previous epidemiological work suggested that atrial cardiopathy itself increases the risk of stroke, even in the absence of atrial fibrillation. We found several biomarkers of atrial cardiopathy, including blood tests, electrocardiogram abnormalities, and structural heart abnormalities seen on ultrasound. If we can identify atrial cardiopathy using these tests, and treat patients with a blood thinner, we might prevent recurrent strokes."

Elkind is a keen mentor. In addition to having led neurology residency and fellowship programmes at Columbia University, he edited the Resident and Fellow Section of *Neurology* for 6 years, and currently edits the new International Stroke Early Career and Training Section (InterSECT) in the *Stroke* journal.

He also chaired the American Stroke Association Advisory Committee (2016--19) and co-chaired several writing committees for scientific guidelines. He is about to face another huge challenge as President of the American Heart Association. "I'm only the second neurologist to take on this role. The AHA is a leading public health organisation and I look forward to expanding its impact by promoting brain health and wellbeing more broadly."

Outside of work, Elkind enjoys spending time with his wife (novelist and children\'s book author Rachel Vail) and their two sons Zachary and Liam. They enjoy skiing, hiking, kayaking, and travelling. And when life in the fast lane gets too much, they have their pet tortoise---Lightning---to slow them all down.
